A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor

Overview

Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and who have had an incomplete response to at least one TNF-alpha inhibitor.

Full Title of Study: “A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 2016

Interventions

  • Drug: Allogeneic Mesenchymal Precursor Cells
  • Drug: Normal Saline

Arms, Groups and Cohorts

  • Placebo Comparator: Normal Saline Placebo
    • Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
  • Active Comparator: Allogeneic Mesenchymal Precursor Cells
    • Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.

Clinical Trial Outcome Measures

Primary Measures

  • Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion
    • Time Frame: 12 weeks post IV Infusion
    • To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 4 months and who have had an incomplete response to at least one course of a TNFα inhibitor. Overall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs and Chest x-ray.

Secondary Measures

  • Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA
    • Time Frame: 12 weeks post IV infusion with MPCs
    • To assess the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to least one TNFα inhibitor.
  • Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA
    • Time Frame: 52 weeks post IV Infusion
    • To evaluate the long-term efficacy and safety of allogeneic MPCs over the entire study duration in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to at least one TNFα inhibitor Safety will be assessed according to the following: Adverse events/serious adverse events (“primary endpoint”) Vital signs Physical examination Clinical laboratory tests Electrocardiogram Chest x-ray (CXR) Efficacy will be assessed according to the following: ACR20/50/70 DAS28 (mean changes from baseline as measured by using hsCRP and ESR) Mean changes from baseline in all components of the ACR core response criteria Remissions (as defined in the 2011 Joint Statement of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) Joint erosion of hands and wrists assessed via x-ray Patient-reported outcomes SF36v2 HAQ_DI

Participating in This Clinical Trial

Inclusion Criteria

  • Males and Females ages 18-80 years old – Active rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification criteria for the diagnosis of RA. – Must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-CCP3) but without extra-articular disease or functional limitation – Patient with active RA defined as: – ≥ 4 tender joint count (TJC) 28 joint count at screening and – ≥ 4 swollen joint count (SJC) count 28 joint count at screening – ESR ≥ 28 mm/hr or hsCRP >2.0 mg/L – Patient has been taking MTX for at least 4 months with dose and route of administration stable for at least 8 weeks prior to screening – Patient has had an inadequate response to at least one TNFα inhibitor with last dose at least 6 weeks prior to screening – Use of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is permitted but must be stable for at least 3 months prior to screening Exclusion Criteria:

  • Pregnant women or women who are breastfeeding. – Other investigational therapy received within 8 weeks or five half-lives (whichever is longer) prior to Screening (except as in exclusion #13). – Known or suspected alcohol or drug abuse within three years preceding Screening. – Autoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis) – History of or current inflammatory joint disease other than RA (such as tophaceous gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis are excluded. – Bedridden or confined to a wheelchair or patients with > 3 arthroplasties due to RA. – History of diagnosed and/or treated malignancy with no evidence of recurrence in past 5 years – Surgical procedures planned to occur during the trial (these patients may be rescreened following completion of and recovery from the surgical procedure). – Use of TNFα inhibitor for treatment of RA at time of screening or within the 6 weeks prior to screening. – Prior use of biologic agent for treatment of RA within 6 weeks prior to screening

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mesoblast, Ltd.
  • Collaborator
    • PPD
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Donna Skerrett, MD, MS, Study Director, Mesoblast, Ltd.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.